152 related articles for article (PubMed ID: 8718527)
1. Molecular genetics of prostate cancer.
Isaacs WB
Cancer Surv; 1995; 25():357-79. PubMed ID: 8718527
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of prostate cancer.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Semin Oncol; 1994 Oct; 21(5):514-21. PubMed ID: 7939745
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of prostate cancer progression.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Cancer Surv; 1995; 23():19-32. PubMed ID: 7621457
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations in prostate cancer.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Cold Spring Harb Symp Quant Biol; 1994; 59():653-9. PubMed ID: 7587126
[TBL] [Abstract][Full Text] [Related]
5. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
Shiina H; Breault JE; Basset WW; Enokida H; Urakami S; Li LC; Okino ST; Deguchi M; Kaneuchi M; Terashima M; Yoneda T; Shigeno K; Carroll PR; Igawa M; Dahiya R
Cancer Res; 2005 Mar; 65(6):2130-8. PubMed ID: 15781623
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven year follow-up.
Crundwell MC; Arkell DG; Gearty J; Phillips SM
J Urol; 1997 Oct; 158(4):1568-75. PubMed ID: 9302175
[TBL] [Abstract][Full Text] [Related]
7. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
Latil A; Cussenot O; Fournier G; Driouch K; Lidereau R
Cancer Res; 1997 Mar; 57(6):1058-62. PubMed ID: 9067271
[TBL] [Abstract][Full Text] [Related]
9. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.
Huang SF; Xiao S; Renshaw AA; Loughlin KR; Hudson TJ; Fletcher JA
Am J Pathol; 1996 Nov; 149(5):1565-73. PubMed ID: 8909246
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of proximal 6q deletions in prostate cancer.
Cooney KA; Wetzel JC; Consolino CM; Wojno KJ
Cancer Res; 1996 Sep; 56(18):4150-3. PubMed ID: 8797584
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation, molecular genetic, and linkage studies in prostate cancer.
Jarrard DF; Bova GS; Isaacs WB
Prostate Suppl; 1996; 6():36-44. PubMed ID: 8630228
[TBL] [Abstract][Full Text] [Related]
13. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors.
Souza RF; Yin J; Smolinski KN; Zou TT; Wang S; Shi YQ; Rhyu MG; Cottrell J; Abraham JM; Biden K; Simms L; Leggett B; Bova GS; Frank T; Powell SM; Sugimura H; Young J; Harpaz N; Shimizu K; Matsubara N; Meltzer SJ
Cancer Res; 1997 Jun; 57(12):2350-3. PubMed ID: 9192806
[TBL] [Abstract][Full Text] [Related]
14. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
15. Alterations of the cadherin-catenin cell adhesion system in cancers.
Kanai Y; Oda T; Shimoyama Y; Ochiai A; Oyama T; Yoshiura K; Akimoto S; Yamada T; Hirohashi S
Princess Takamatsu Symp; 1994; 24():51-62. PubMed ID: 8983063
[TBL] [Abstract][Full Text] [Related]
16. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features.
Wei Y; Van Nhieu JT; Prigent S; Srivatanakul P; Tiollais P; Buendia MA
Hepatology; 2002 Sep; 36(3):692-701. PubMed ID: 12198663
[TBL] [Abstract][Full Text] [Related]
17. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
Vécsey-Semjén B; Becker KF; Sinski A; Blennow E; Vietor I; Zatloukal K; Beug H; Wagner E; Huber LA
Oncogene; 2002 Jul; 21(30):4646-62. PubMed ID: 12096341
[TBL] [Abstract][Full Text] [Related]
18. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
19. Genetic and molecular aspects of human multigenerational carcinogenesis.
Evans HJ
IARC Sci Publ; 1989; (96):315-33. PubMed ID: 2553599
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
